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ABSTRACT Biofilm-associated polymicrobial infections, particularly those involving fungi and bacteria, are responsible for sig-
nificant morbidity and mortality and tend to be challenging to treat. Candida albicans and Staphylococcus aureus specifically are
considered leading opportunistic fungal and bacterial pathogens, respectively, mainly due to their ability to form biofilms on
catheters and indwelling medical devices. However, the impact of mixed-species biofilm growth on therapy remains largely un-
derstudied. In this study, we investigated the influence of C. albicans secreted cell wall polysaccharides on the response of S. au-
reus to antibacterial agents in biofilm. Results demonstrated significantly enhanced tolerance for S. aureus to drugs in the pres-
ence of C. albicans or its secreted cell wall polysaccharide material. Fluorescence confocal time-lapse microscopy revealed
impairment of drug diffusion through the mixed biofilmmatrix. Using C. albicansmutant strains with modulated cell wall poly-
saccharide expression, exogenous supplementation, and enzymatic degradation, the C. albicans-secreted !-1,3-glucan cell wall
component was identified as the key matrix constituent providing the bacteria with enhanced drug tolerance. Further, antibody
labeling demonstrated rapid coating of the bacteria by the C. albicansmatrix material. Importantly, via its effect on the fungal
biofilmmatrix, the antifungal caspofungin sensitized the bacteria to the drugs. Understanding such symbiotic interactions with
clinical relevance betweenmicrobial species in biofilms will greatly aid in overcoming the limitations of current therapies and in
defining potential new targets for treating polymicrobial infections.
IMPORTANCE The fungus Candida albicans and the bacterium Staphylococcus aureus are important microbial pathogens re-
sponsible for the majority of infections in hospitalized patients and are often coisolated from a host. In this study, we demon-
strated that when grown together, the fungus provides the bacteriumwith enhanced tolerance to antimicrobial drugs. This pro-
cess was mediated by polysaccharides secreted by the fungal cell into the environment. The biofilmmatrix formed by these
polysaccharides prevented penetration by the drugs and provided the bacteria with protection. Importantly, we show that by
inhibiting the production of the fungal polysaccharides, a specific antifungal agent indirectly sensitized the bacteria to antimi-
crobials. Understanding the therapeutic implications of the interactions between these two diverse microbial species will aid in
overcoming the limitations of current therapies and in defining new targets for treating complex polymicrobial infections.
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Polymicrobial infections caused by a combination of micro-organisms are responsible for significant mortality and
morbidity, particularly those associated with biofilms formed
on indwelling medical devices (1–3). Biofilms are structured
three-dimensional communities of surface-associated micro-
bial populations embedded in a matrix of extracellular polysac-
charides, proposed to provide a structural scaffold and protec-
tion for biofilm cells (4–6). Therefore, in a biofilm, microbes are
afforded a stable environment and can tolerate high concentra-
tions of antimicrobials. The impact of these biofilms on public
health is dramatic, as cells released from biofilms canmigrate into
the bloodstream and cause systemic infectionswith highmortality
(7). Importantly, the increase in drug resistance has provided a
strong impetus to understand the mechanisms of the enhanced
tolerance of biofilm-associated infections to antimicrobial ther-
apy and particularly polymicrobial infections. Although mixed
fungal-bacterial infections tend to be the most complex and chal-
lenging to treat, the impact of these interactions on therapy re-
mains largely understudied.
Among the fungal species, Candida albicans is the most com-
mon human pathogen, causing diseases ranging from superficial
mucosal to life-threatening systemic infections (8–10). The ability
of C. albicans to transition from commensal to pathogen is pri-
marily the result of its aptitude for morphologically switching be-
tween yeast and hyphal forms (9, 11). In fact, the majority of
C. albicans infections are associated with its ability to form bio-
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films, where adhesion of yeast cells to the substrate is followed by
proliferation and hypha formation, resulting in a network of cells
embedded in amatrix (7, 12, 13).Candida albicans biofilmmatrix
is complex, with major polysaccharide constituents being
!-mannan, "-1,6-glucan, and "-1,3-glucan (14, 15). Although a
relatively minor component, "-1,3-glucan is considered the crit-
ical matrix polysaccharide, as extracellular glucan has been linked
to biofilm resistance to antifungals (16, 17). In fact, previous stud-
ies have shown elevated "-1,3-glucan levels to be characteristic of
biofilm cells both in the fungal cell walls and as a secreted form.Of
more significance, the increase in "-1,3-glucan secretion by bio-
film cells was shown in vivo in animal models of catheter infection
and disseminated candidiasis (12). Glucan synthase Fks1p is re-
sponsible for the synthesis of cell wall"-1,3-glucan during biofilm
growth, and FKS1 disruption was shown to reduce manufacture
and deposition of"-1,3-glucan in the biofilmmatrix (18). Impor-
tantly, using strains with modulated FKS1 expression, a study by
Nett et al. (18) demonstrated that reduction in expression ren-
dered biofilms more susceptible to various antifungals, whereas
overexpression resulted in increased resistance.
In various niches in the host, C. albicans coexists with various
bacterial species, including Staphylococcus aureus (2, 19–21). Al-
though S. aureus primarily exists as a commensal organism, this
bacterial pathogen is implicated in a variety of diseases ranging
from minor skin infections to more serious invasive diseases and
specifically device-associated biofilm infections (22–24).With the
emergence of methicillin-resistant S. aureus (MRSA), this ubiqui-
tous pathogen is becoming an even greater therapeutic challenge
(25, 26). S. aureus is a poor former of biofilms; however, together
withC. albicans, this species forms a substantial biofilm where the
fungus creates a scaffold for the bacteria (27–29). Our previous in
vitro studies have demonstrated that S. aureus exhibits high affin-
ity to the C. albicans hyphal form, as these species coadhere and
interact synergistically in a biofilm. Further, our studies identified
the C. albicans hypha-specific adhesin Als3p to be involved in the
coadherence process (27).
The growing use of implanted medical devices is another rea-
son why the incidence of Candida and staphylococcal infections
has steadily increased, since the majority of these infections are
emerging from biofilms formed on medical implants (10, 13, 23,
30, 31). In fact, a recent analysis of cases of endocarditis associated
with an implanted device found ~25% of the infections to be
polymicrobial, and in another study, 27% of nosocomial C. albi-
cans bloodstream infections were estimated to be polymicrobial
(32, 33). Importantly, S. aureus was found to be the third most
commonly coisolated species with C. albicans (33). Although nu-
merous studies have reported the coisolation of C. albicans and
S. aureus from a multitude of diseases such as periodontitis, den-
ture stomatitis, cystic fibrosis, keratitis, ventilator-associated
pneumonia, and urinary tract catheter and burn wound infec-
tions, the clinical significance of their interaction in a host remains
largely understudied, likely due to lack of suitable animal models
(34–38). However, using a mouse model of oral infection, we re-
cently demonstrated that upon onset of oral candidiasis (thrush),
mice cocolonized with C. albicans and S. aureus suffered systemic
bacterial infection with high morbidity and mortality (39).
The inherent characteristics of biofilms are multifactorial but
are largely due to the extracellular matrix encasing the biofilm
cells, which prevents drugs and other stresses frompenetrating the
biofilm. Therefore, S. aureus andC. albicans interactions inmixed
biofilm infectionsmay also impact response to antimicrobial ther-
apy (39). Although enhanced in vitro tolerance to antimicrobials
in C. albicans and staphylococcus mixed biofilms has been re-
ported, the mechanism and specific factors behind these observa-
tions remain undefined (40, 41). To that end, in this study, exper-
iments were designed to demonstrate the impact of C. albicans
biofilm matrix and secreted components on the susceptibility of
S. aureus to antibacterial drugs in biofilm, focusing on vancomy-
cin, the drug of choice for treatment of MRSA infections. The
overall goal of this study is to provide crucial insights into the
enhanced tolerance of biofilm-associated polymicrobial infec-
tions to antimicrobial therapy.
RESULTS
Comparative assessment of the susceptibility of S. aureus to
vancomycin in single and mixed biofilms with C. albicans. The
impact ofmixed-species biofilm growth on S. aureus susceptibility
to vancomycin was assessed following 24-h treatment of pre-
formed single and mixed biofilms. Based on CFU, results demon-
strated a significant increase in S. aureus survival inmixed biofilms
following vancomycin treatment compared to survival in single
biofilm (Fig. 1A). Analysis of biofilms using crystal violet staining
indicated a significant increase in biofilm biomass in mixed bio-
films relative to S. aureus biofilm (Fig. 1B). These results were
corroborated by scanning electron microscopy (SEM) analysis
where images of mixed biofilms revealed a thick matrix, with
S. aureus adhering to and forming aggregates around the C. albi-
cans hyphae (Fig. 1C and D).
Exogenous supplementation of S. aureus biofilmswithC. al-
bicans biofilm matrix material enhances S. aureus tolerance to
vancomycin. To isolate the role of C. albicans biofilm matrix in
the enhanced tolerance of S. aureus to vancomycin in mixed bio-
films, purifiedmatrixmaterial recovered fromC. albicans biofilms
was incorporated in susceptibility testing. Assessment of S. aureus
viability by the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] metabolic
assay and CFU recovery demonstrated a significant increase in
S. aureus survival in single biofilms formed in the presence of
matrix material (Fig. 2). In order to identify the contribution of
specific matrix components, similar experiments were also per-
formed where S. aureus biofilms were allowed to form in the pres-
ence of glucan or mannan. Results from these experiments dem-
onstrated a comparable increase in survival with vancomycin.
Differential C. albicans !-1,3-glucan but not "-mannan ex-
pression modulates vancomycin tolerance in mixed biofilms.
The key role for the "-1,3-glucan matrix component was demon-
strated using C. albicans strains with modulated "-1,3-glucan ex-
pression in mixed biofilms treated with vancomycin. Compared
to their respective reference strains, S. aureus recovery following
vancomycin treatment was consistently higher in the presence of
the TDH3-FKS1 glucan-overexpressing strain but lower when
grownwith the FKS1/fks1! glucan-deficient heterozygousmutant
strain (Fig. 3A). No impact on S. aureus vancomycin susceptibility
was seen inmixed biofilmswith themannosylationmutants or the
zap1!/zap1!mutant lacking the zinc response transcription fac-
tor Zap1 (a negative regulator of "-1,3-glucan) (data not shown).
!-1,3-Glucanase but not"-mannosidase treatment ofmixed
biofilms abrogates the enhanced tolerance to vancomycin. To
demonstrate the importance of theC. albicansmatrix polysaccha-
rides, experiments were also performed where single- and mixed-
Kong et al.
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species biofilms were treated with vancomycin in the presence of
the glucan-degrading enzyme Zymolyase or the mannan-
degrading enzyme !-mannosidase. Based on CFU recovery, the
increase in S. aureus vancomycin tolerance in mixed biofilms was
significantly diminished upon Zymolyase treatment, to a level
comparable to that for S. aureus single-species biofilm treatedwith
vancomycin. However, no significant differences were noted with
the !-mannosidase treatment (Fig. 3B). Since Zymolyase is
known to have contaminating protease activity, enzymatic diges-
tion experiments were also performed using proteinase K; results
from these experiments demonstrated no effect for proteinase K
on S. aureus response to vancomycin (data not shown).
SEM of S. aureus biofilm architecture supplemented with
C. albicans biofilm matrix material and exogenous !-1,3-
glucan. To visualize the structure of the S. aureus biofilm supple-
mented with C. albicans matrix material, S. aureus biofilms were
allowed to form for 24 h in the absence and presence of purified
matrix material or glucan, and the formed biofilms were compar-
atively examined by SEM analysis. Images revealed that where
nonsupplemented S. aureus biofilms appeared thin and heteroge-
neous (Fig. 4A and B), growth in the presence of matrix material
(Fig. 4C and D) or "-1,3-glucan (Fig. 4E and F) resulted in signif-
icantly increased biofilm mass with considerable aggregation of
bacterial cells.
C. albicans spent culture medium provides S. aureus with
enhanced tolerance to vancomycin in single-species biofilm.
Since C. albicans cell wall polysaccharides are secreted, experi-
ments were performed where C. albicans spent biofilm culture
medium was recovered and used in vancomycin susceptibility
testing of S. aureus single biofilms. Results from these experiments
demonstrated that C. albicans cell-free spent medium provided
S. aureus with significantly enhanced tolerance to vancomycin in
the absence of C. albicans in the biofilm (Fig. 5A). To identify the
secreted component conferring the tolerance, the spent medium
FIG 1 Assessment of relative biomass and vancomycin susceptibility in single S. aureus (SA) and mixed S. aureus and C. albicans (SA/CA) biofilms. (A)
Preformed (24-h) S. aureus single and mixed biofilms were treated with vancomycin (800 #g/ml) for an additional 24 h. CFU recovery of S. aureus from both
biofilms showed a significant increase in S. aureus recovery frommixed biofilms following vancomycin treatment (***, P" 0.001). (B) To assess biomass, 24-h
single- and mixed-species biofilms were treated with crystal violet. Based on absorbance (595 nm), results demonstrated significantly higher biomass for mixed
biofilms than for S. aureus biofilm (**, P" 0.01; ***, P" 0.001). Means and standard errors of the means are shown. (C and D) These results were corroborated
by SEM analysis where images demonstrated adherence to and clumping of S. aureus around C. albicans hyphae, forming thick biofilm aggregates.
FIG 2 Effect of C. albicansmatrix polysaccharides on S. aureus (SA) suscep-
tibility to vancomycin. S. aureus single biofilms were allowed to form in the
presence of purified C. albicans (CA) biofilm matrix material (0.02 mg/liter),
glucan (1 mg/ml), or mannan (1 mg/ml). S. aureus dual-species biofilms were
grown withC. albicans (SA/CA). Preformed biofilms were treated with vanco-
mycin (800 #g/ml) for 24 h. S. aureus CFU recovery from biofilms demon-
strated significant increase in S. aureus tolerance to vancomycin in the pres-
ence of matrix material, glucan, and mannan. Susceptibility to vancomycin
was assessed by CFU counts and corroborated by an MTS assay (**, P" 0.01;
***, P" 0.001). Means and standard errors of the means are shown.
Fungal-Bacterial Biofilms and Drug Resistance
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was enzymatically pretreated with Zymolyase or !-mannosidase
prior to use in vancomycin susceptibility assays. Results from
these experiments demonstrated that, whereas Zymolyase treat-
ment considerably diminished the observed protection in spent
medium (Fig. 5B), !-mannosidase treatment had no significant
impact on S. aureus susceptibility to vancomycin (data not
shown). Zymolyase and !-mannosidase treatment alone did not
have any effect on S. aureus viability.
Inhibition of !-1,3-glucan synthesis in C. albicans compro-
mises the enhanced tolerance to vancomycin in mixed biofilms
and of spent medium. In addition to enzymatic degradation, the
antifungal caspofungin, an inhibitor of "-1,3-glucan synthesis in
the fungal cell, was used to assess whether its effect on cell wall
glucan synthesis impacts S. aureus vancomycin susceptibility.
Prior to experiments, the subinhibitory caspofungin concentra-
tion on C. albicans was determined using the MTS assay and CFU
FIG 3 Effect of C. albicans FKS1 modulation and Zymolyase treatment on S. aureus (SA) susceptibility to vancomycin. (A) Preformed S. aureus single- and
mixed-species biofilms with the various C. albicans strains were treated for 48 h with vancomycin (800 #g/ml). Based on CFU recovery, a significant increase in
S. aureus survival was seen when grown in mixed biofilms with the TDH3-FKS1 glucan-overexpressing strain compared to its parent strain SC5314, whereas a
significant decrease in survival was noted when S. aureus was grown with the glucan-deficient heterozygous FKS1/fks1 mutant strain compared to its parental
strain BWP17 (***, P" 0.0001). (B) S. aureus single (SA) and mixed (CA/SA) biofilms were allowed to form for 24 h in the presence of Zymolyase (5 U/ml) or
!-mannosidase (2 U/ml) and then treated with vancomycin (800 #g/ml) for 24 h. Based on CFU recovery, although growth with C. albicans in mixed biofilms
provided S. aureuswith a significant increase in survival with vancomycin, the increase in tolerance was diminished upon treatment with Zymolyase but not with
!-mannosidase (*, P" 0.05; ***, P" 0.0001; ns, not significant). Means and standard errors of the means are shown.
FIG 4 Effect of purified matrix and glucan supplementation on S. aureus biofilm architecture using SEM analysis. (A and B) Images of S. aureus biofilms
demonstrated a thin and heterogeneous biofilm formed following a 48-h incubation. (C to F) In contrast, when grown in the presence of exogenous matrix
material (0.5 mg/ml) (C and D) or glucan (0.25 mg/ml) (E and F), significant increases in biofilm matrix, mass, and bacterial cell clumping were seen.
Kong et al.
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enumeration to determine its effect on metabolic activity and vi-
ability, respectively. Results from the MTS assay indicated a
concentration-dependent decrease in C. albicansmetabolic activ-
ity with caspofungin; however, no effect on viability was noted for
these concentrations (Fig. 6A and B). The selected subinhibitory
caspofungin concentration (0.5 #g/ml) was subsequently used in
mixed biofilm vancomycin susceptibility assays. Based on CFU
recovery, results demonstrated a significant decrease in S. aureus
survival with vancomycin when mixed biofilms were treated with
caspofungin (Fig. 6C). Further, experiments were also performed
to determine whether the effect of caspofungin on "-1,3-glucan
synthesis affects its secretion and, thus, the protective effect of
C. albicans spent medium on S. aureus. Therefore, experiments
were also performed where formed C. albicans biofilms were
treated with caspofungin prior to recovering the spent culture
medium, which was subsequently used in vancomycin suscepti-
bility testing. Results from these experiments similarly demon-
strated that caspofungin treatment of C. albicans biofilms signifi-
cantly diminished the ability of recovered spentmedium to confer
protection against vancomycin on S. aureus (Fig. 7). Caspofungin
did not have any effect on S. aureus.
Impeded vancomycin diffusion through S. aureus biofilms
grown with C. albicans or its purified and secreted matrix ma-
terial. Vancomycin diffusion through single and mixed biofilm
matrices was comparatively monitored using fluorescence confo-
cal scanning laser microscopy (CSLM). S. aureus biofilms were
grown with C. albicans, with purified C. albicans biofilm matrix
material, or in C. albicans spent culture medium with secreted
material. Formed biofilms were stained with concanavalin A
(ConA) to allow visualization of the polysaccharide matrix (red).
To visualize vancomycin diffusion through the matrix, a fluores-
cently tagged vancomycin compound was used. After 1 h, vanco-
mycin (cyan) had significantly penetrated and diffused through-
out the single S. aureus biofilm matrix, reaching the basal layer
(Fig. 8A). In contrast, in the mixed biofilms with C. albicans, van-
comycin signal wasminimally detected, with negligible to no pen-
etration into the matrix seen (Fig. 8B). Similarly, in the biofilms
formed with exogenous supplementation with C. albicansmatrix
material, vancomycin was confined to the outer periphery of the
biofilmwithminimal to no penetration into the biofilm (Fig. 8C),
and in biofilms grown in spentmedium, only limited vancomycin
penetration into the biofilm was seen (Fig. 8D).
S. aureus cell coating by C. albicans purified and secreted
biofilm matrix components. In order to evaluate whether C. al-
bicansmatrix polysaccharides also coat the bacterial cells, S. aureus
planktonic cell suspensionwas incubated withC. albicans purified
matrix and coatingwas assessed usingmonoclonal antibodies spe-
cific to each of the C. albicansmatrix components. Using fluores-
cencemicroscopy, images demonstrated rapid coating of all 3ma-
trix components (!-mannan, "-1,3-glucan, and "-1,6-glucan) as
assessed by the presence of fluorescence around the bacterial cells.
S. aureus cells not treated with matrix demonstrated no fluores-
cence when labeled with antibodies. In addition to purified ma-
trix, to determine whether the secreted matrix material similarly
coats the bacterial cells, experiments were also performed where
S. aureus was incubated in the C. albicans spent culture medium.
Labeling of bacterial cells with the three specific antibodies dem-
onstrated the presence of all matrix components around the sur-
face of S. aureus cells (Fig. 9).
Enhanced tolerance of S. aureus in mixed biofilm is not an-
tibiotic,methicillin resistance, or S. aureus strain dependent. In
order to determine whether the C. albicans-conferred enhanced
tolerance of S. aureus inmixed biofilm is exclusive to vancomycin-
or methicillin-resistant strains of S. aureus, susceptibility assays
were also performed using two additional antibiotics, oxacillin
and nafcillin. Further, the susceptibility of a methicillin-
susceptible S. aureus (MSSA) strain was also tested against all 3
antibiotics in biofilms with C. albicans. Based on S. aureus CFU
recovery, results demonstrated that, similarly to vancomycin, the
MRSA strain exhibited enhanced tolerance to both oxacillin and
nafcillin in mixed biofilm (see Fig. S1 in the supplemental mate-
rial). A comparable increase in tolerance to all three antibiotics
was also seen with the MSSA strain (data not shown).
FIG 5 Effect of secreted effectors in C. albicans spent medium on S. aureus (SA) vancomycin susceptibility. (A) Supernatant from C. albicans culture
medium (spent medium) was collected and used in S. aureus vancomycin susceptibility testing assays. Based on results from S. aureus CFU recovery,
growth in C. albicans spent medium significantly enhanced S. aureus vancomycin tolerance compared to growth in control fresh medium (*, P " 0.05).
(B) Since C. albicans-produced glucan is secreted into the medium, spent medium was treated with Zymolyase prior to vancomycin susceptibility testing.
No significant effect for Zymolyase alone on S. aureus viability was seen; however, S. aureus tolerance to vancomycin was significantly diminished when
spent medium was treated with Zymolyase. Results were corroborated with an MTS assay (*, P" 0.05; **, P" 0.001; ***, P" 0.0001; ns, not significant).
Means and standard errors of the means are shown.
Fungal-Bacterial Biofilms and Drug Resistance
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DISCUSSION
Traditional therapies for biofilm-associated infections involve re-
moval of infected devices, in addition to multidrug administra-
tion that is generally aimed at individual causative agents without
consideration for effect on a polymicrobial cause. However, the
medical community is recognizing the significance of polymicro-
bial diseases, and many therapies are now taking into account the
cause of these conditions and the repercussions for treatment and
prevention (42). Therefore, understanding the physical and mo-
lecular interactions between diverse microorganisms will greatly
aid in defining new strategies for disrupting these complex mixed
infections (20, 30, 33, 43).
Production of extracellular matrix polysaccharides is consid-
ered one of the key resistance mechanisms in microbial biofilms,
and recent efforts have been focused on understanding the genetic
basis for how biofilm matrix production governs drug resistance
(16). In exploring the influence of C. albicans biofilm matrix on
antifungal susceptibility, studies by Nett et al. (44) demonstrated
that the matrix sequestered azole antifungal drugs and prevented
them from reaching their target. In this study, we sought to dem-
onstrate thatC. albicansmatrixmay similarly confer protection on
other microbial species against their respective antimicrobials
when coexisting within mixed biofilms. Specifically, we explored
the efficacy of antibacterial drugs against S. aureus in mixed
fungal-bacterial biofilms, focusing on the role of the C. albicans
"-1,3-glucan matrix component.
Our experiments using C. albicans strains with inhibition or
overexpression of FKS1 and concomitant variations inmatrix glu-
can amount decreased or increased S. aureus susceptibility to van-
comycin, respectively (Fig. 3A). It is important to note that the
strain with decreased FKS1 expression used in our experiments is
a heterozygous and not a null mutant, as FKS1 is a vital gene,
which makes the observed decrease in vancomycin susceptibility
with this strain more significant.
Importantly, by supplementing S. aureus single-species bio-
films with exogenous C. albicans biofilm-derived purified matrix
FIG 6 Effect of caspofungin treatment of mixed biofilms on response of
S. aureus (SA) to vancomycin. (A) In order to determine the C. albicans (CA)
sublethal, inhibitory concentration of caspofungin, susceptibility assays were
performed where preformed C. albicans biofilms were treated with caspofun-
gin for 24 h. Results from theMTS assay indicated a concentration-dependent
decrease in C. albicans metabolic activity with caspofungin. (B) However, no
significant effect on C. albicans viability was noted for these concentrations
based on CFU enumeration (*, P" 0.05; ***, P" 0.0001; ns, not significant).
(C) Mixed species biofilms were similarly treated with caspofungin and van-
comycin (800 #g/ml), and S. aureus viability was assessed by CFU recovery.
Results demonstrated a significant decrease in S. aureus survival with vanco-
mycin when mixed biofilms were treated with 0.5 #g/ml caspofungin (*, P"
0.05). Means and standard errors of the means are shown.
FIG 7 Effect of caspofungin treatment of C. albicans (CA) biofilms on ability
of spent culture medium to confer vancomycin tolerance. C. albicans biofilms
were treated with caspofungin (0.5 #g/ml) in order to diminish glucan syn-
thesis and secretion. Recovered spent culture medium was then used in van-
comycin (400 #g/ml) susceptibility testing of S. aureus (SA) single-species
biofilms. Based on S. aureus CFU recovery, results demonstrated that caspo-
fungin treatment of C. albicans biofilms significantly diminished the ability of
the spent medium to provide S. aureus with protection against vancomycin.
Results were also corroborated by anMTS assay (**, P" 0.01; ***, P" 0.001).
Means and standard errors of the means are shown.
Kong et al.
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material or individualmatrix components, we were able to induce
the S. aureus resistance phenotype in the absence of C. albicans
(Fig. 2). However, experiments probing the role of matrix man-
nan using the mannan-degrading enzyme !-mannosidase, and
various C. albicans mannosylation-deficient mutant strains,
yielded no notable difference in S. aureus susceptibility to vanco-
mycin. Further evidence for the role of secreted "-1,3-glucan was
demonstrated by findings that C. albicans spent culture medium
enhanced S. aureus tolerance to vancomycin; however, the ac-
quired tolerance was significantly diminished when the spent me-
dium was treated with the "-1,3-glucan-degrading enzyme but
not the mannan-degrading enzyme (Fig. 3B). These findings are
FIG 8 Representative CSLM images assessing diffusion of fluorescently labeled vancomycin through S. aureus grown with C. albicans or its derived
biofilm matrix material or in spent medium. S. aureus biofilms were grown for 24 h with C. albicans or supplemented with 0.5 mg/ml of purified matrix
material. S. aureus biofilms were also grown in C. albicans spent culture medium containing secreted matrix components. Biofilms were stained with
ConA for biofilm matrix (red) and fluorescent vancomycin compound (cyan). Following a 1-h diffusion, the biofilms were visualized using CSLM. (A)
In the S. aureus monospecies biofilms, vancomycin fully penetrated and diffused throughout the biofilm matrix (white; red/cyan merged), reaching the
basal layers. (B) In contrast, in mixed biofilms with C. albicans, minimum vancomycin presence or diffusion was seen. (C) Similarly, in biofilms grown
with C. albicans matrix material, vancomycin presence was limited to the surface of the biofilm, with no or minimal penetration into the biofilm. (D) In
biofilms grown in spent medium, there was limited penetration of vancomycin into the biofilm matrix and diffused vancomycin was present in greatly
reduced concentrations.
Fungal-Bacterial Biofilms and Drug Resistance
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in line of those of Nett et al. (44), where glucanase but not
!-mannosidase increasedC. albicans susceptibility to the antifun-
gal agent fluconazole. Combined, these findings identify "-1,3-
glucan as the key matrix component contributing to S. aureus
vancomycin tolerance in mixed biofilms with C. albicans.
Of interest, a study by De Brucker et al. (45) had reported a
similar phenomenon involving the tolerance of the Gram-
negative bacterial species Escherichia coli to the antibiotic ofloxa-
cin in mixed biofilm, and analogously to our findings, "-1,3-
glucan was shown to be involved. These observations are
interesting in light of our findings that in mixed biofilm, in addi-
tion to vancomycin, S. aureus also exhibited enhanced tolerance to
other antibiotics, namely, oxacillin and nafcillin. Importantly, in
testing anMSSA strain with all three antibiotics in mixed biofilm,
we also demonstrated that the effect of C. albicans on S. aureus
susceptibility is not S. aureus strain dependent or associated with
methicillin resistance. Of note and in contrast to our findings, the
C. albicans zap1!/zap!mutant strainwas shown to provide E. coli
with increased, albeit minimal, tolerance to ofloxacin.
The C. albicans zinc response transcription factor Zap1 was
identified by Nobile et al. (46) as a negative regulator of "-1,3-
glucan, and the zap1!/zap1! strain was found to produce more
soluble "-1,3-glucan in biofilms. However, we found no signifi-
cant difference in S. aureus tolerance between growth with this
mutant and that with the parental strain (data not shown). These
discrepancies are intriguing as Zap1 was also shown to govern
synthesis of small, secretedmolecules involved in quorum sensing
(QS) or interspecies communication. Specifically, Zap1 acts as a
positive regulator of the accumulation of farnesol, a QS molecule
secreted by C. albicans in biofilm, where the zap1!/zap1!mutant
accumulated significantly less farnesol (46). Interestingly, in a pre-
vious study, our findings showed that exogenous synthetic farne-
sol impacted S. aureus susceptibility to various antibiotics, indi-
cating a potential role for this molecule in the C. albicans-
mediated modulation of the S. aureus response to vancomycin
(47). Hence, it is conceivable to speculate that any potential nota-
ble enhanced effect for the zap1!/zap1! mutant on vancomycin
responsemay have been neutralized by the compromised produc-
tion and secretion of farnesol by the zap1!/zap1!mutant. Com-
bined, these observations are of significance as they indicate that
QS may also play an important role in mediating the process of
enhanced antimicrobial tolerance in biofilm. Therefore, it is im-
portant tomaintain that although this study focuses onC. albicans
biofilmmatrix components, polymicrobial biofilm formation and
antimicrobial resistance are a multifactorial process involving all
microbial partners, and thus, the contribution of S. aureus to the
process cannot be disregarded.
One interesting question is whether the C. albicans matrix
components, in addition to serving as a barrier, directly bind
vancomycin. To explore this possibility, we performed explor-
atory experiments using the vancomycin antibody in immuno-
assays to assess polysaccharide binding to vancomycin. How-
ever, due to the inherent “stickiness” of the matrix material,
these and other experiments were problematic and therefore
inconclusive. Nevertheless, the demonstration that the mixed
biofilm also conferred protection against other antibacterial
agents argues against specific binding to vancomycin being a
significant contributor.
Vancomycin is one of the few antibiotics that have remained
effective against methicillin-resistant S. aureus, and develop-
ment of resistance to vancomycin is relatively rare (48). There-
fore, the demonstration of the failure of vancomycin to effec-
tively penetrate the dense mixed biofilm matrix, as shown in
our diffusion imaging (Fig. 8), carries significant clinical im-
plications, as this process may be indicative of a potential ther-
apeutic outcome in a host with a coinfected indwelling medical
device. Of similar clinical relevance is the finding that at con-
centrations subinhibitory to C. albicans, the antifungal caspo-
fungin sensitized the matrix-embedded S. aureus cells to van-
comycin (Fig. 6C).
FIG 9 Fluorescence microscopy of S. aureus coated with purified and secreted soluble C. albicans biofilm matrix material. S. aureus planktonic cultures were
grown for 24 h in the presence of 0.1 mg/ml of purified matrix or in C. albicans spent culture medium. Following washing, cells were treated with !-mannan-,
"-1,3-glucan-, and "-1,6-glucan-specific antibodies (Abs) (30 min); stained with a secondary antibody (30min); and then examined by CSLM. Images revealed
the presence of all three matrix components around the bacterial cells when grown with purified matrix material. No fluorescence was detected in control cells
frombiofilmgrownwithoutmatrix. Control cells grown in the absence ofmatrix did not fluoresce but could be visualized by Syto9 staining. Cells were also grown
inC. albicans spent culturemedium (nomatrix supplementation) in order to assess whether secretedmatrix components also coat bacterial cells. Similar to what
was seen with the purified matrix, cells fluoresced when labeled with the antibodies. Control cells grown in fresh medium did not fluoresce but could be seen by
Syto9 staining.
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In conclusion, this study provides compelling evidence dem-
onstrating the therapeutic impact of C. albicans cell wall secreted
polysaccharide components on a bacterial coinhabitant in amixed
biofilm. To our knowledge, this is the first study utilizing confocal
fluorescent time-lapse imaging to visually monitor antimicrobial
diffusion through a mixed biofilm. Further, using monoclonal
antibodies specific to fungal cell wall components, we demon-
strate rapid coating of the bacterial cell by secreted C. albicans cell
wall polysaccharides. These novel findings are of significance as
they may indicate that in addition to hampering diffusion of an-
timicrobials in a biofilm, the coating of the bacterial cell by fungal
secreted polysaccharides may offer the bacteria added protection
by preventing the drug from reaching its cellular target (Fig. 10).
Therefore, the combined findings from this study warrant aware-
ness in terms of optimizing and overcoming the limitations of
current therapies available to treat resilient polymicrobial infec-
tions. Importantly, it is crucial to develop suitable animal models
to study these phenomena in vivo, and such investigations are
ongoing in our laboratory.
MATERIALS AND METHODS
Reagents. "-1,3-Glucan (laminarin from Laminaria digitata), lyticase
from Arthrobacter luteus (Zymolyase), mannan (from Saccharomyces
cerevisiae), concanavalin A (from Canavalia ensiformis), !-mannosidase
(from jack bean), proteinase K from Tritirachium album, and oxacillin
sodium and nafcillin sodiumwere purchased from Sigma-Aldrich Chem-
ical (St. Louis, MO); the MTS tetrazolium-based proliferation assay was
fromPromega (Madison,WI); vancomycin hydrochloridewas fromHos-
pira Inc. (IL, USA); Syto9 green fluorescent nucleic acid stain and vanco-
mycin dipyrromethene boron difluoride (BODIPY) FL conjugate were
from Invitrogen (Grand Island, NY); and FUN1 fungal stain was from
Thermo Fisher Scientific (Halethorpe, MD).
Strains and growth conditions. The standard methicillin-resistant
S. aureus (MRSA) strain USA300 and the methicillin-susceptible (MSSA)
strain ATCC 29213 were used in these studies (49). The following C. al-
bicans strains were used where indicated: C. albicans reference strains
SC5314 (50) and DAY185; heterozygous deletion mutant (FKS1/fks1!)
constructed from BWP17, FKS1-overexpressing mutant (TDH3-FKS1)
with one FKS1 allele under the control of the TDH3 promoter and one
allele intact (18); zap1!/zap1! homozygous deletion strain (CJN1201)
and the ZAP1/zap1! complemented strain (CJN1193) (46); the mnn4!
(51) and mnn9! (52) mannosylphosphate transferase mutants with re-
duced phosphomannan and mannan, respectively; and the mnt1! and
mnt2! !-1,2-mannosyltransferase mutants and mnt1!/mnt2! double
mutant (53). C. albicans strains were maintained on yeast-peptone-
dextrose (YPD) agar (Difco Laboratories) and grown in YPD broth over-
night at 30°C with orbital shaking, and cells were equilibrated in fresh
medium to an optical density of absorbance of 1.0 at 600 nm. S. aureus
cultures were grown overnight in Trypticase soy broth (TSB) (Difco) at
37°C and then grown in fresh TSB tomid-log phase. Cells were harvested,
washed, and resuspended in RPMI 1640 with L-glutamine and HEPES
(Invitrogen, Grand Island, NY) and used at final cell densities of 1 #
106 cells/ml.
In vitro single- and mixed-species biofilm formation. Biofilms were
grown in the wells of 96-well polystyrene flat-bottom plates. C. albicans
and S. aureus cell suspensions were adjusted to 1# 106 cells/ml in RPMI
medium, and 100 #l of cell suspensions was added to the wells individu-
ally or in combination. Plates were incubated for 90min at 37°C, and then
wells were washed twice with phosphate-buffered saline (PBS) to remove
nonadherent cells. Fresh medium (200 #l) was added to each well, and
biofilms were allowed to form for 24 h at 37°C. Following incubation,
wells were washed with PBS.
CV staining of biofilms. Single andmixed biofilm biomass was quan-
tified using the crystal violet (CV) assay with modifications (54). Biofilms
were grown as described above and then washed twice with PBS and air
dried at 37°C. Biofilms were stained with 1% aqueous CV solution for
20 min and then washed with sterile water. Plates were air dried, and
remaining CV stain was dissolved using 33% acetic acid solution. Follow-
ing 45 min of destaining, 150 #l of destaining solution was transferred to
FIG 10 Schematic representation of the proposed “barrier model” as a mechanism for the enhanced S. aureus tolerance to vancomycin in mixed biofilm.
Based on the combined findings from this study, we propose that the mechanism for the enhanced S. aureus tolerance to vancomycin involves impediment
of diffusion of antimicrobials through the mixed biofilm matrix consisting of C. albicans hyphae and secreted cell wall polysaccharides; !-mannan,
"-1,3-glucan, and "-1,6-glucan secreted by C. albicans into the mixed biofilm environment adhere to the S. aureus cell surface, coating the outer layer.
Concurrently, as the biofilm matures, in addition to providing structure and support to the biofilm, the secreted matrix polysaccharides impede the
diffusion of antimicrobials into the biofilm interior. Effectively, the polysaccharide matrix acts as a barrier, sequestering vancomycin at the periphery and
preventing it from reaching its target.
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a new well, and the amount of CV stain was measured with a microtiter
plate reader at 595 nm (Titertek; Multiskan MCC1340).
Biofilm vancomycin susceptibility testing. The impact of C. albicans
on the response of S. aureus to vancomycinwas assessed in biofilms grown
as described above.Mixed biofilmswere grownusing S. aureus and each of
the C. albicansmutant strains for 24 h. Following washing, the wells were
supplemented with fresh medium, vancomycin hydrochloride at a final
concentration of 800 #g/ml (predetermined based on activity against
S. aureus single and mixed biofilms) (see Fig. S2 in the supplemental
material) was added, and plates were incubated for an additional 24 h at
37°C. Biofilms were then washed twice with PBS, and 100 #l of PBS was
added; cells from the biofilms were recovered by sonication followed by
vigorous vortexing and pipetting. Cell suspensions were diluted and
plated on C. albicans and S. aureus-specific chromogenic medium
(CHROMagar; DRG International, Inc.) for CFU count. Drug-free wells
were included as controls. In addition, in order to assess the effect of
mixed biofilm growth on S. aureus susceptibility to other antibiotics, ex-
periments were also performed using two additional antibiotics, oxacillin
(0 to 480 #g/ml) and nafcillin (0 to 160 #g/ml). Further, susceptibility
testing using all 3 antibiotics was performed using an alternate strain of
S. aureus that is susceptible to methicillin (MSSA).
MTS assay. Viability was also assessed using the MTS metabolic assay
according to the manufacturer’s directions. Following washing with PBS,
100#l of PBSwas added to thewells followed by 20#l ofMTS reagent and
plates were incubated at 37°C until color fully developed. Following color
development, colorimetric change at 490 nm (A490) was measured with a
microtiter plate reader. On each occasion, reactions were performed in
triplicate.
SEM of single- and mixed-species biofilms. For SEM analysis, S. au-
reus was grown in single species biofilm with and without exogenous
supplementation of purified matrix material (0.5 mg/ml) or glucan
(0.25mg/ml) or withC. albicans in mixed biofilms, on coverslips for 48 h.
Coverslips were washed twice with PBS and then fixed in 2% paraformal-
dehyde, 2.5% glutaraldehyde in phosphate buffer, pH 7.4, for 1 h at room
temperature and then at 4°C overnight. Following initial fixation, speci-
mens were washed in three changes of 0.1 M PBS for a total of 30 min,
postfixed with 1% osmium tetroxide in PBS for 1 h, and washed again in
three changes of buffer. Dehydration of specimens was done using a series
of graded ethyl alcohol, 30%, 50%, 70%, 90%, and 100% for 10min each,
and twomore changes of 100% ethyl alcohol. Specimens were then chem-
ically dried by immersing them sequentially in 2 parts 100% ethyl
alcohol-1 part hexamethyldisilazane (HMDS) (Electron Microscopy Sci-
ences, FortWashington, PA) for 10 min, 1 part 100% ethyl alcohol-1 part
HDMS for 10 min, 1 part 100% ethyl alcohol-2 parts HDMS for 10 min,
and then 2 changes for 10min eachwith 100%HDMS. Specimenswere air
dried in a hood overnight, mounted on SEM pin mounts, and sputter
coated with 10 to 20 nm of platinum-palladium in a sputter coater (EMS
150T ES). SEM images were captured using a Quanta 200 scanning elec-
tron microscope (FEI Co., Hillsboro, OR).
Effect of C. albicans purified biofilm-derived matrix material and
!-1,3-glucan and mannan exogenous supplementation on S. aureus
susceptibility to vancomycin in single-species biofilm. C. albicans ma-
trix polysaccharides were extracted fromC. albicans biofilms and purified
as previously described (55). The recoveredmatrix material (0.25mg/ml)
was used to supplement S. aureus biofilms, whichwere allowed to form for
24 h as described above. S. aureus biofilms were also formed in the pres-
ence of exogenous "-1,3-glucan (1 mg/ml) or mannan (1 mg/ml) as pre-
viously performed (44). Following incubation, biofilms were washed and
supplemented with fresh RPMI medium and vancomycin (800 #g/ml),
and plates were incubated for an additional 24 h. Following washing,
S. aureus viability was assessed using the MTS assay and confirmed by
CFU recovery for viability.
Impact of C. albicans !-1,3-glucan and mannan enzymatic degra-
dation on S. aureus susceptibility to vancomycin in mixed biofilms.
Prior to performing experiments, susceptibility of C. albicans to Zy-
molyase and !-mannosidase was tested to determine the subinhibitory
concentrations to be used in mixed biofilm susceptibility testing. Mixed-
species biofilms were grown alone or in the presence of glucanase (Zy-
molyase) (5U/ml) or!-mannosidase (2U/ml). Vancomycin (800#g/ml)
was then added alone or in combination with the enzymes, and plates
were incubated for an additional 24 h at 37°C. Following incubation, wells
were washed three times with PBS and biofilm cells were recovered by
sonication and plated for CFU counts. In order to demonstrate lack of
contribution of contaminating protease activity in Zymolyase, experi-
ments were also performed using enzymatic digestion with proteinase K.
Impact of inhibition of C. albicans in !-1,3-glucan synthesis on
S. aureus susceptibility to vancomycin in mixed biofilms. Mixed 24-h
biofilms were treated with the "-1,3-glucan synthase inhibitor caspofun-
gin at final concentrations of 0, 0.06, and 0.5 #g/ml with and without
vancomycin (800 #g/ml), and plates were incubated for an additional
24 h. Following washing, biofilms were sonicated and S. aureus viability
was assessed based on CFU counts. Prior to experiments, susceptibility of
C. albicans to caspofungin in single species was assessed in order to deter-
mine the subinhibitory caspofungin concentration to be used in mixed
biofilms. Viability was evaluated using the MTS assay to determine
changes in metabolic activity and CFU enumeration for viability.
Effect of C. albicans soluble secreted matrix components on S. au-
reus susceptibility to vancomycin. In order investigate the role of C. al-
bicans secreted matrix components on vancomycin susceptibility, cell-
free C. albicans biofilm spent culture medium was recovered. Briefly,
C. albicans (1 # 106 cells/ml) biofilms were grown in 10 ml of RPMI
medium in canted-neck flasks and incubated at 37°C for 48 h. Following
incubation, spent culture medium was recovered and filter sterilized
through a 0.22-#mpore. The filteredmediumwas then supplemented 1:1
with fresh RPMI medium (prewarmed to 37°C) and used to grow S. au-
reus single-species biofilms. Following 24-h incubation, biofilms were
washed and then supplemented with fresh medium and vancomycin
(400 #g/ml) (predetermined to be subinhibitory in S. aureus single-
species biofilm) (see Fig. S2 in the supplemental material) and incubated
for an additional 24 h. S. aureus viability was assessed using theMTS assay
and based on CFU recovery. To identify "-1,3-glucan as the key secreted
component in C. albicans culture medium, experiments were also per-
formed where S. aureus biofilms were cultured in the spent medium (as
described above) with the addition of 5 U/ml of the glucan-degrading
enzyme glucanase (Zymolyase) for 24 h at 37°C. Following incubation,
vancomycin susceptibility testing was performed. Spent mediumwithout
glucanase was included as a control. In addition,C. albicans biofilms were
grown for 24 h and then treated with the "-1,3-glucan synthesis inhibitor
caspofungin (0.5 #g/ml) (subinhibitory dose for C. albicans) for an addi-
tional 24 h. Spent medium was then collected and used in vancomycin
susceptibility testing of S. aureus single-species biofilms as described
above.
Confocal scanning laser microscopy analysis of vancomycin diffu-
sion through single andmixed biofilms. To visualize the process of van-
comycin diffusion through single and mixed biofilms, confocal scanning
laser microscopy was performed as based on a previously described
method for S. aureus with modifications (48). In addition to monitoring
vancomycin diffusion through mixed biofilms, experiments were also
performed where S. aureus single biofilms were formed in the presence of
exogenous supplementation of purified C. albicans biofilm matrix to iso-
late the role of the matrix. Further, as matrix components are secreted
during C. albicans growth, biofilm spent culture medium was used to
grow S. aureus biofilms. For these experiments, biofilms were grown on
glass coverslip-bottom dishes (MatTek Co., Ashland, MA) in RPMI me-
dium at 37°C for 24 h. Following incubation, biofilms were gently washed
three times with PBS and stained with concanavalin A (ConA) for poly-
saccharide biofilm matrix (100 #g/ml) (red; 488/545). In order to visual-
ize the diffusion of vancomycin, the fluorescent BODIPY FL conjugate of
vancomycin (cyan; 488/650) was added to the biofilms to a final concen-
tration of 1#g/ml. Biofilms were incubated for 1 h and then washed three
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times with PBS to remove nonpenetrated vancomycin and observed using
a 63# oil immersion objective and a Zeiss 710 confocal microscope. Im-
ages were obtained by LSM 5 Image Browser software at a resolution of
512 by 512 pixels, with an average of 8 images per line. To evaluate the
structure and size of the biofilms, a series of images at$1-#m intervals in
the z axis were acquired for the full depth of the biofilm. At least three
random fields were visualized for each biofilm, and representative images
are presented.
Fluorescence microscopy analysis of S. aureus cell coating with pu-
rified and secreted solubleC. albicans biofilmmatrixmaterial. In order
to examine whether, in addition to their role in biofilms, purified and
secretedmatrix components also coat the bacterial cell, S. aureus cells (2#
107 cells/ml) were incubated with 0.1 mg/ml of the purified matrix
material for 30 min at 37°C. S. aureus cells with no matrix treatment
were included as controls. In addition to purified matrix, experiments
were also performed where S. aureus was exposed to C. albicans spent
culture medium in order to determine whether soluble matrix com-
ponents secreted by C. albicans during biofilm growth similarly coat
the bacterial cells. In these experiments, 2 # 107 cells/ml of S. aureus
were incubated with 1 ml of C. albicans spent medium for 30 min at
37°C. S. aureus cells incubated in fresh medium were included as a
control. Following three washes with PBS, cells were treated with
monoclonal antibodies specific to !-mannan (1/100 dilution), "-1,3-
glucans (1/6,000 dilution), and "-1,6-glucans (1/4,000 dilution) (pro-
duced as previously described) (14) for 1 h at 37°C. Following incuba-
tion with primary antibodies, cells were washed three times with PBS
and subsequently incubated with a goat anti-mouse IgG Alexa Fluor
488 (orange; 495/519) secondary antibody (1/100 dilution) (Thermo
Fisher Scientific) for 30 min at 37°C. Cells were then washed, pelleted,
and resuspended in 50 #l PBS. One drop of cell suspension was placed
on a slide and covered with a coverslip, and fluorescence was assessed
by CSLM. Non-matrix-coated S. aureus cells similarly treated with the
antibodies were used as a control. However, as control cells with no
matrix did not react with antibodies and therefore were not visible,
they were stained with Syto9 nucleic acid stain (10 #M) (green; 488/
505) in order to be visualized. Cells were observed using a 63# oil
immersion objective and a Zeiss 710 confocal microscope. Images
were obtained by LSM 5 Image Browser software at a resolution of 512
by 512 pixels, with an average of 8 images per line. At least three
random fields were visualized for each sample, and representative im-
ages are presented.
Data analysis. All experiments were performed on at least 3 separate
occasions and in triplicate where applicable, and averages were used to
present data. All statistical analysis was performed using GraphPad Prism
5.0 software. The Kruskal-Wallis one-way analysis of variance test was
used to compare differences between multiple groups, and Dunn’s
multiple-comparison test was used to determine whether the difference
between two samples was statistically significant. Student’s unpaired t test
was used to compare differences between two samples. P values of$0.05
were considered to be significant.
SUPPLEMENTAL MATERIAL
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